Results 91 to 100 of about 114,702 (262)

Bruton’s Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE?

open access: yesImmunoTargets and Therapy, 2020
Ana Lorenzo-Vizcaya,1 Serena Fasano,2 David A Isenberg3 1Department of Internal Medicine, Hospital Universitario De Ourense, Ourense, Spain; 2Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Campania L.
Lorenzo-Vizcaya A, Fasano S, Isenberg DA
doaj  

New Methods in Treatment of Renal failure in Patients with Multiple Myeloma: A Review with Immunological Approach. [PDF]

open access: yes, 2017
Multiple myeloma (MM), as one of a variety of autoimmune diseases, affects the immune system and, on the other hand, is considered to be a hematologic impairment.
Iranparast, Sara.   +2 more
core   +1 more source

Sequence of Immunological Events During IgE‐Mediated Allergic Reactions to Food

open access: yesAllergy, EarlyView.
ABSTRACT Food allergies (FA) represent a significant global health burden. Upon allergen re‐exposure, allergic patients exhibit a sequence of symptoms that vary in terms of affected organ systems, severity, time of onset and allergen reactivity thresholds.
N. A. Nagy   +7 more
wiley   +1 more source

The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodies

open access: yesHaematologica, 2017
Acalabrutinib is a new, irreversible Bruton tyrosine kinase (BTK) inhibitor, reported to be more selective than ibrutinib.[1][1]–[3][2] BTK inhibitors are often combined with anti-CD20 antibodies in the clinic, but ibrutinib interferes with some of the ...
J. Golay, Greta Ubiali, M. Introna
semanticscholar   +1 more source

Unmet Needs in Treatment Escalation for Chronic Spontaneous Urticaria: Findings From the CURE Registry

open access: yesAllergy, EarlyView.
Appropriate treatment escalation improves CSU disease control. However, only about a quarter of patients achieve a complete response, the main goal of CSU treatment. Approximately one‐third of patients clinically eligible for escalation (UCT < 12) do not receive guideline‐recommended treatment escalation and remain symptomatic on their current ...
Pavel Kolkhir   +25 more
wiley   +1 more source

Gene expression patterns following unilateral traumatic brain injury reveals a local pro-inflammatory and remote anti-inflammatory response. [PDF]

open access: yes, 2013
BackgroundTraumatic brain injury (TBI) results in irreversible damage at the site of impact and initiates cellular and molecular processes that lead to secondary neural injury in the surrounding tissue.
Ford, Byron D   +5 more
core   +2 more sources

Phase Ib dose-escalation study of the selective, noncovalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies

open access: yesHaematologica, 2021
Not available.
J. Allan   +18 more
semanticscholar   +1 more source

The International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria

open access: yesAllergy, EarlyView.
ABSTRACT This update and revision of the international guideline for urticaria was developed in accordance with the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is an initiative of the Global Allergy and Asthma Excellence Network (GA2LEN) and its Urticaria and ...
T. Zuberbier   +221 more
wiley   +1 more source

Exploring the association of disease-modifying therapies for multiple sclerosis and BTK inhibitors with epilepsy

open access: yesTherapeutic Advances in Neurological Disorders
Background: Multiple lines of evidence suggest a role of inflammation in epilepsy. Seizure incidence in patients with multiple sclerosis (MS) is twofold to threefold higher than the age-matched general population.
Afsaneh Shirani   +6 more
doaj   +1 more source

Coming of Age for BTK Inhibitor Therapy: A Review of Zanubrutinib in Waldenström Macroglobulinemia

open access: yesCells, 2022
Waldenström macroglobulinemia (WM) is a rare form of non-Hodgkin B-cell lymphoma with a variable clinical presentation that can impact a patient’s quality of life by causing anemia, peripheral neuropathy, serum hyperviscosity, extramedullary disease, and
Javier Muñoz   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy